Benutzer: Gast  Login
Titel:

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Dokumenttyp:
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Autor(en):
Pirker, R; Pereira, JR; Szczesna, A; von Pawel, J; Krzakowski, M; Ramlau, R; Vynnychenko, I; Park, K; Yu, CT; Ganul, V; Roh, JK; Bajetta, E; O'Byrne, K; de Marinis, F; Eberhardt, W; Goddemeier, T; Emig, M; Gatzemeier, U
Abstract:
BACKGROUND: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer. METHODS: In a multinational, multicentre, open-label, phase III trial, chemotherapy-naive patients (>or=18 years) with advanced EGFR-expressing histologically...     »
Zeitschriftentitel:
Lancet
Jahr:
2009
Band / Volume:
373
Heft / Issue:
9674
Seitenangaben Beitrag:
1525-31
Sprache:
eng
Volltext / DOI:
doi:10.1016/S0140-6736(09)60569-9
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/19410716
Print-ISSN:
0140-6736
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX